金斯瑞生物科技(01548.HK):傳奇生物第四季度收益大增110% 全年研發開支達2.32億美元
格隆匯3月8日丨金斯瑞生物科技(01548.HK)公吿,截至2020年12月31日止年度,公司附屬傳奇生物科技股份有限公司取得收益7567.6萬美元,同比增長32.15%;期間研發開支達2.32億美元,同比增長43.36%。
截至2020年12月31日止3個月,傳奇生物收益為4080萬美元,上年同期為1950萬美元,同比增長110%。增加2130萬美元主要是由於確認因根據傳奇生物與楊森的協議實現額外里程牌的付款而獲得的更多收益,並解除相關受限制可變代價。
研發開支同比增加主要是由於該年度臨牀試驗數量增加、參加有關試驗的患者人數增加及研發候選產品數量增加。
傳奇生物首席執行官及首席財務官黃穎博士表示:“今年是傳奇生物決定性的一年,傳奇生物實現了重要的管線進展,並完成了首次公開發售和在納斯達克上市。儘管新冠肺炎疫情帶來挑戰,但傳奇生物在2020年仍然表現強勁,且2021年延續了這一勢頭,腫瘤管線計劃取得重大進展。通過與楊森生物科技有限公司(楊森)的合作,傳奇生物在2020年啟動了西達基奧侖賽(cilta-cel)的全球三期研究,並作為綜合臨牀開發計劃的一部分擴展了多隊列二期研究,包括用於治療早期多發性骨髓瘤。2021年,公司預計將在推進cilta-cel的監管審批程序中實現重要的里程碑”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.